Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.
Conditions
Interventions
Pomalidomide
Dexamethasone
+1 more
Locations
49
United States
Local Institution - 126
Tucson, Arizona, United States
Local Institution - 137
Greenbrae, California, United States
Local Institution - 109
Los Angeles, California, United States
Local Institution - 104
Pleasant Hill, California, United States
Local Institution - 108
Whittier, California, United States
Local Institution - 138
Denver, Colorado, United States
Start Date
May 29, 2014
Primary Completion Date
April 30, 2025
Completion Date
May 26, 2025
Last Updated
June 6, 2025
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions